Latest News

  • Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences Read More
  • Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™ Read More
  • Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting Read More

Investors

Working at Alkermes